Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus DERMABET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus DERMABET.
ARAZLO vs DERMABET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Betamethasone dipropionate is a corticosteroid that diffuses across cell membranes and binds to glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and decreasing the synthesis of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply a thin layer to affected area once or twice daily. Maximum 50 g per week.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life: 3-4 hours; prolonged in hepatic impairment
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal (60-70% as unchanged drug and metabolites), biliary/fecal (30-40%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid